Verrica Pharmaceuticals Inc. (VRCA) financial statements and ratios from SEC XBRL: revenue $35.58M (TTM), net margin -50.3%, revenue growth 370.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $35.58M |
| Net Margin | -50.3% |
| Revenue Growth (YoY) | 370.2% |
| EPS Growth (YoY) | 13.5% |
| FCF Growth (YoY) | -71.1% |
| Price / Book | 5.18 |
| Price / Sales | 2.34 |
| FCF Yield | -43.0% |
| Altman Z-Score | -6.86 (distress) |
| Sector P/E (Healthcare) | 21.7 |
VRCA overview · VRCA earnings · VRCA KPIs · VRCA investor relations · VRCA ownership · VRCA peers · VRCA filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.